Markets:

Overview

News

Currencies

International

Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.6376 -0.0441 (-6.47%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Lexaria Bioscience Receives Award For Oral Nicotine Compound Patent ↗

March 09, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a...

Via Benzinga

Studies Advance Lexaria Bioscience's Tech For Improving Pharmaceutical Drugs ↗

March 07, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience is dedicated to...

Via Benzinga

Lexaria's DehydraTECH(TM) Demonstrates Faster Delivery Of Sildenafil ↗

March 04, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)...

Via Benzinga

Lexaria Bioscience Optimistic Of Positive Study Results ↗

February 28, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....

Via Benzinga

Lexaria Optimistic About Expanded DehydraTECH Investigations ↗

February 23, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria just announced ground-breaking...

Via Benzinga

Lexaria World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech ↗

February 22, 2022

Photo by Shelby Ireland on Unsplash

Via Benzinga

Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study ↗

January 28, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Following Sildenafil Study, Lexaria Announces Plans For More Studies In 2022 ↗

February 17, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria’s animal study could be...

Via Benzinga

Lexaria's DehydraTECH(TM) To Be Evaluated As Treatment For Multiple Conditions ↗

February 14, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)...

Via Benzinga

Lexaria Technology Shows Promise In Improving Performance Of ED Drugs ↗

February 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Health and wellness drug bio-...

Via Benzinga

Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders ↗

February 09, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. In 2021, Lexaria conducted several main studies evaluating...

Via Benzinga

Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study ↗

February 03, 2022

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study.

Via Benzinga

Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast ↗

February 01, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Chris Bunka, the Chairman and CEO of Lexaria, featured on the...

Via Benzinga

Lexaria Bioscience Marks Great Start to its 2022 R&D Programs ↗

January 21, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review...

Via Benzinga

Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2 ↗

January 19, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a...

Via Benzinga

Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine ↗

January 18, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX...

Via Benzinga

Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution ↗

January 12, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience’s ongoing...

Via Benzinga

Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study ↗

January 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received approval from the...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

January 07, 2022

Gainers ContraFect (NASDAQ:CFRX) stock mo...

Via Benzinga

Lexaria Bioscience Increases Investor Visibility with SRAX ↗

January 07, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The strategic move to incorporate...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 06, 2022

Gainers ContraFect (NASDAQ:CFRX) stock in...

Via Benzinga

Lexaria Bioscience Announces Approval from Independent Review for DehydraTECH-CBD Study ↗

December 30, 2021

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-...

Via Benzinga

Lexaria Bioscience Expects Study Results to Show Patented Tech's Value in Treating Hypertension ↗

December 28, 2021

Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating...

Via Benzinga

Lexaria Bioscience Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD ↗

December 23, 2021

In a recent human clinical trial, HYPER-H21-2, DehydraTECH-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat...

Via Benzinga

Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study ↗

December 17, 2021

Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood...

Via Benzinga

Lexaria Bioscience Committed to Innovation and Improving Quality of Life ↗

December 15, 2021

Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical...

Via Benzinga

Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B ↗

December 13, 2021

Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 10, 2021

Gainers Reshape Lifesciences (NASDAQ:RSLS...

Via Benzinga

52 Biggest Movers From Yesterday ↗

December 09, 2021

Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to...

Via Benzinga

Lexaria Bioscience Featured in Virtual Coverage of Benzinga's Small Cap Conference ↗

December 08, 2021

Lexaria Bioscience (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve the delivery of...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

Headline News about Lexaria Bioscience Corp. - Common Stock

Starting at $3.75/week.

Subscribe Today